Carcinome hépatocellulaire avancé: importance des essais thérapeutiques [Advanced hepatocellular carcinoma: importance of clinical trials]
Details
Serval ID
serval:BIB_7B026B899673
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Carcinome hépatocellulaire avancé: importance des essais thérapeutiques [Advanced hepatocellular carcinoma: importance of clinical trials]
Journal
Revue medicale suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
20/05/2015
Peer-reviewed
Oui
Volume
11
Number
475
Pages
1149-1151
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
In hepatocellular carcinoma, sorafenib is the only active medical treatment validated to date. Sorafenib is a targeted therapy mainly blocking tumor vascularisation. Sorafenib is currently used for inoperable or advanced stages of hepatocellular carcinoma, as well for hepatocellular carcinoma recurrence when the disease is diffuse or multifocal. Current clinical trials are designed to identify new antitumor molecules active in hepatocellular carcinoma that could enrich the therapeutic armamentarium in addition to sorafenib.
Keywords
Antineoplastic Agents/therapeutic use, Benzenesulfonates/therapeutic use, Carcinoma, Hepatocellular/pathology, Carcinoma, Hepatocellular/therapy, Clinical Trials as Topic/statistics & numerical data, Disease Progression, Humans, Liver Neoplasms/pathology, Liver Neoplasms/therapy, Niacinamide/analogs & derivatives, Patient Selection, Phenylurea Compounds, Sorafenib
Pubmed
Create date
03/04/2023 11:46
Last modification date
04/04/2023 6:54
Usage data
